Anti-ferritin polyclonal antibody

Drug Profile

Anti-ferritin polyclonal antibody

Alternative Names: Ferritarg P; Ferritarg-P - MABLife

Latest Information Update: 18 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAT Biopharma
  • Developer MABLife
  • Class Antineoplastics; Polyclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Iron-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hodgkin's disease

Most Recent Events

  • 18 Sep 2015 No recent reports on development identified - Phase-I/II for Hodgkin's disease in France (IV)
  • 29 Jul 2011 MAT Biopharma has been renamed as MABLife
  • 22 Feb 2011 Ferritarg® is still in phase I/II development for refractory Hodgkin's lymphoma in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top